MedPath

Fluconazole

Generic Name
Fluconazole
Brand Names
Diflucan
Drug Type
Small Molecule
Chemical Formula
C13H12F2N6O
CAS Number
86386-73-4
Unique Ingredient Identifier
8VZV102JFY
Background

Fluconazole, commonly known as Diflucan, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an azole antifungal, in the same drug family as ketoconazole and itraconazole. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.

Indication

Fluconazole can be administered in the treatment of the following fungal infections:

1) Vaginal yeast infections caused by Candida

2) Systemic Candida infections

3) Both esophageal and oropharyngeal candidiasis

4) Cryptococcal meningitis

5) UTI (urinary tract infection) by Candida

6) Peritonitis (inflammation of the peritoneum) caused by Candida

A note on fungal infection prophylaxis

Patients receiving bone marrow transplantation who are treated with cytotoxic chemotherapy and/or radiation therapy may be predisposed to candida infections, and may receive fluconazole as prophylactic therapy.

A note on laboratory testing

Obtaining specimens for fungal culture and other important laboratory studies such as serology or pathology is advised before starting fluconazole therapy in order to isolate the organisms to be eliminated through treatment. It is permissible to start therapy before the results are available, however, adjusting the therapy once laboratory results confirm the causative organism may be necessary.

Associated Conditions
Candida intertrigo, Candida pneumonia, Candida urinary tract infection, Candidemia, Candidiasis, Coccidioidomycosis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Meningitis, Cryptococcal, Oropharyngeal Candidiasis, Peritoneal candidiasis, Pneumonia cryptococcal, Pruritus, Skin Irritation, Systemic Candida Infections caused by Candida, Vaginal Candidiasis, Disseminated Candidiasis

A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2021-12-01
Last Posted Date
2021-12-01
Lead Sponsor
Acerta Pharma BV
Target Recruit Count
30
Registration Number
NCT05140096
Locations
🇺🇸

Celerion, Tempe, Arizona, United States

A Study in Healthy Men to Test How Fluconazole Influences the Amount of BI 425809 in the Blood

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2021-10-13
Last Posted Date
2022-01-12
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
15
Registration Number
NCT05076409
Locations
🇩🇪

Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis

Phase 3
Conditions
Recurrent Vulvovaginal Candidiasis
Interventions
First Posted Date
2021-10-12
Last Posted Date
2021-10-12
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
196
Registration Number
NCT05074602
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

A Clinical Trial for Chlorhexidine as Treatment for Vulvovaginal Candidiasis

Phase 2
Recruiting
Conditions
Candidiasis, Vulvovaginal
Interventions
First Posted Date
2021-09-28
Last Posted Date
2022-05-20
Lead Sponsor
Karolinska Institutet
Target Recruit Count
60
Registration Number
NCT05059145
Locations
🇸🇪

Danderyd Hospital, Dep. of Obstetrics and Gynecology, Stockholm, Sweden

A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Acute Vulvovaginal Candidiasis

Phase 3
Conditions
Acute Vulvovaginal Candidiasis
Interventions
Drug: SHR8008 capsule
First Posted Date
2021-07-09
Last Posted Date
2021-09-16
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
322
Registration Number
NCT04956419
Locations
🇨🇳

Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China

SD-OCT Guided Treatment of Fungal Chorioretinitis

Conditions
Fungal Retinitis
First Posted Date
2021-07-01
Last Posted Date
2021-12-15
Lead Sponsor
Benha University
Target Recruit Count
10
Registration Number
NCT04947592
Locations
🇦🇪

INMC, Abu Dhabi, United Arab Emirates

Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2021-06-22
Last Posted Date
2022-12-08
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
16
Registration Number
NCT04933682
Locations
🇺🇸

Clinical Trial Site, Tempe, Arizona, United States

Vulvovaginal Candidiasis in Canadian Females

Early Phase 1
Recruiting
Conditions
Candidiasis, Vulvovaginal
Interventions
Drug: Boric Acid Supp,Vag
First Posted Date
2021-06-18
Last Posted Date
2024-02-15
Lead Sponsor
University of Manitoba
Target Recruit Count
105
Registration Number
NCT04930107
Locations
🇨🇦

Health Science Centre (HSC), Winnipeg, Manitoba, Canada

Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects

Phase 1
Completed
Conditions
RSV Infection
Interventions
First Posted Date
2021-05-04
Last Posted Date
2021-05-04
Lead Sponsor
Enanta Pharmaceuticals, Inc
Target Recruit Count
24
Registration Number
NCT04871724
Locations
🇺🇸

Pharmaceutical Research Associates, Inc.,, Salt Lake City, Utah, United States

A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC)

Phase 2
Active, not recruiting
Conditions
Recurrent Vulvovaginal Candidiasis
Interventions
Drug: Placebo capsule
Drug: Placebo cream
First Posted Date
2021-02-02
Last Posted Date
2022-09-22
Lead Sponsor
ProFem GmbH
Target Recruit Count
432
Registration Number
NCT04734405
Locations
🇦🇹

Universitätsklinik für Gynäkologie und Geburthilfe, Uni-Klinik IBK, Innsbruck, Tirol, Austria

🇵🇱

Centrum Zdrowia Kobiety Komed,, Kielce, Poland

🇦🇹

Ambulatorium für Pilzinfektionen und andere infektiöse venero-dermatologische Erkrankungen, Wien, Austria

and more 26 locations
© Copyright 2025. All Rights Reserved by MedPath